Researchers trialling an experimental drug on critically ill coronavirus patients say it prevented their disease from progressing in 79% of cases. The experimental drug known as SNG001 is an inhaled formulation of beta-interferon developed by the pharmaceutical company Synairgen and was given to patients in hospital with COVID-19 who needed oxygen assistance.
Coronavirus: Trial shows experimental drug prevents 79% of COVID-19 cases from progressing
